The US FDA has filed a motion to dismiss Teva Pharmaceutical Industries' recent lawsuit regarding the loss of its first-filer marketing exclusivity on generic versions of Merck & Co's antihypertensives, Cozaar (losartan potassium) and Hyzaar (losartan plus hydrochlorothiazide).
Teva has pending ANDAs for its generic versions, and the case involves a situation where a brand firm has voluntarily...
Welcome to Scrip
Create an account to read this article
Already a subscriber?